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Abstract  
AIM: The aim of this study was to investigate the influence of subclasses to IgG anti-D on the 
intensity of hemolytic disease of fetus and newborn (HDFN) at 45 fetuses/newborns with symptoms 
of mild and severe HDFN in Republic of Macedonia. 
MATERIAL AND METHODS: In retrospective and prospective studies, in a period of 10 years, 
from 2004 to 2014, there have been immunohemathology tests performed on 22 009 samples on 
serums of pregnant women.  
RESULTS: At 37.78% of the total number of tested patients, IgG1 and IgG3 was the reason for 
severe HDFN. At 17.77% of the total number of tested patients, which had only IgG1detected, was 
the reason for serious intensity of HDFN. The correlation of the titer to anti-D antibodies in the 
mother’s serum and the intensity of HDFN were researched in 48 newborns. The titers between 1:8 
and 1:32 resulted in 3 cases of HDFN with symptoms of severe disease and in 4 cases there were 
no signs of HDFN. At 12 women that had a titre between 1:32 and 1:512, five of the newborns 
developed severe HDFN, and seven had symptoms of mild and weak intensity form. In 3 cases the 
titer was higher than 512, and out of them one newborn had weak symptoms of HDFN, one 
developed severe HDFN and one ended with foetal death. Only in one case the titer reached a 
value higher than 1000, and it ended with a fetal death. 
CONCLUSIONS: The titers of the pregnant women serum those are lower than 32 and those 
higher than 1000 can well predict HDFN. The titers of anti-D antibodies between 64 and 512 have 
no exact predictive value. IgG1 and IgG3 subclasses of anti-D have no predictive value by 
themselves, and cannot foresee the outcome of HDFN. The research study results suggest that 
IgG1 and IgG3 should be included in a multi – parameter protocol for evaluation of the HDFN 
intensity. They can give a real assessment of the expected HDFN intensity in combination with the 
titer hight and the significance of the antibodies. 
 
 
 
 
 
Introduction 
 
 The Rh blood group system contains more 
than 40 antigens with extreme antigenicity. According 
to its importance regarding immune hematology it 
stands right next to the ABO system. It belongs to the 
group of trans-membrane proteins.  
 Basically, three Rh epitopes are defined 
within it, the Rho or the D antigen, which can be 
present or not, denoting Rh positive (D+), or Rh 
negative (D- or d) phenotype.  
 The Rh locus is assigned to the chromosome 
1 (1p34.3-p36.13), it has two genes nearby the Rh 
locus that are responsible for the Rh protein, RHD и 
RHCE [1] D-positive individuals inherit both gens RHD 
and RHCE, while D-negative individuals inherit one 
RHCE gen from each parent. The deployment of the 
RHCE gene is used in general sense in order to mark 
the Rh gen which does not succeed to produce an 
antigen D.  
 Four common genes produce different 
combinations out of C, E, c and e: RHCE, RHCe, 
RHcE, and RHce. Besides the Rh gens, another gen 
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which relates to RHAG (Rh – associated glycoprotein) 
is located in the chromosome 6 (6p11-p21.1), and it is 
connected to the Rh protein on the level of the red 
blood cell membrane [2].  
 The Rh genes act as autosomous co 
dominant alleles. The genetic material that codes C/c 
and E/e is tightly linked to one that controls D, that’s 
why the RH locus is considered as a unique gen 
complex during calculation of gen frequency. 
 
Figure 1: Scheme of the Rh gen 
 
Taking into consideration the available Rh 
antiserums (anti-D, anti-C, anti-c, anti-E, anti-e), the 
Rh phenotype of the tested red blood cells can be 
serologically defined. Accordingly, based on the 
phenotype and gen frequency regarding the tested 
population, the most probable Rh genotype can be 
estimated.  
Table 1: Frequency of common Rh genotypes 
Haplotype Rh gens 
White 
population 
Black 
population 
Americans Asian 
R1 
RHD, 
RHCEe 
0.42 0.17 0.44 0.70 
R RHce  0.37 0.26 0.11 
R2 RHD, RHcE 0.14 0.11 0.34 0.21 
R0 RHD, RHce 0.04 0.44 0.02 0.03 
r’ RHCe  0.02 0.02 0.02 
R’’ RHcE  0.01 0.00 0.06 
Rz RHD, RHCE 0.00 0.00 0.06 0.01 
r
y
 RHCE  0.00 0.00 0.00 
 
Still, family research is the best way of 
establishing the right phenotype. 
Exposure of D-negative individuals to D-
positive red blood cells through transfusion or 
pregnancy, most probably will provoke an immune 
response. Transfusion of approximately 250 ml of D-
positive red blood cells causes production of anti-D at 
about 80% of accidental D-negative recipients [3]. A 
significantly lower amount of red blood cells 
(approximately 1ml) will also stimulate production of 
anti-D at 50% of the D-negative recipients. 
Most Rh antibodies are IgG, and usually 
IgG1, IgG3, or a combination of these two subclasses. 
The production of Rh antibodies is most often caused 
by transfusion or pregnancy. 
The Rh antibodies are clinically significant 
and cause post-transfusion reactions and HDFN. The 
Rh antibodies, since they are primarily IgG1 and IgG3, 
cross through the placenta and can cause HDFN of 
various intensity. HDFN is directly dependant on the 
development of the red blood cell antigens on the 
surface of the fetal red blood cells. The D antigen can 
be detected in fetal red blood cells in the 5 to 6 
gestation week [4, 5]. The antibodies persist for a 
longer period, 6 – 38 years [5].  
HDFN is a clinical syndrome in which the 
basic pathophysiology disorder is the haemolytic 
anaemia of the fetus/newborn. HDFN starts during 
intrauterine life, and the reason for the disease is 
appearance of IgG antibodies that occur as a result of 
the mother’s alloimmunisation towards red blood cell 
antigens of the foetus that are inherited from the 
father, and are not present in the mother [6]. 
The application of RhD immune globulin 
prophylaxis up till 72 hours after giving birth, 
decreases the percentage of RhD sensibilisation to 
1.5% or 2%, and the application of antenatal 
prophylaxis even lowered this percentage from 0.5% 
to 0.1% [7]. 
The present situation of application of 
antenatal, even postnatal prophylaxis in Republic of 
Macedonia is partial and incomplete. It does not 
comprise all pregnant women that are at risk of RhD 
sensibilisation. Unofficial data display that the 
prevalence of RhD sensibilisation in Republic of 
Macedonia is twice higher compared to the rest of the 
countries in Europe and the world, and it moves from 
0,1% to maximum 2% [8-10]. 
The aim of this study was to investigate the 
influence of subclasses to IgG anti-D on the intensity 
of HDFN at 45 fetuses/newborns with symptoms of 
mild and severe HDFN in Republic of Macedonia. 
 
 
Material and Methods 
 
In retrospective and prospective studies, in a 
period of 10 years, from 2004 to 2014, there have 
been immune hematology tests performed on 22,009 
samples on serums of pregnant women: ABO, Rh 
blood group phenotypization; screening of anti red 
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blood cell alloantibodies during pregnancy and after 
delivery with indirect antiglobuline test with five panels 
of red blood cell antigens, enzyme test with two 
panels of red blood cell antigens; direct antiglobuline 
test and elution of antibodies of the newborn red blood 
cells; identification of anti red blood cell antibodies 
with IAT and enzyme panel; quantification of 
antibodies with the titer method; blood group 
phenotypization of adequate antigens towards which 
antibodies were detected, regarding the mother, 
biological father and the newborn. All methods were 
performed according the producers recommendation 
and the Technical Manual, 14
th
 ed., American 
Association of Blood Banks [11]. 
Anti red blood cell antibodies were detected 
towards the antigens of the Rh system at 205 
pregnant women, by identification of a total of 237 anti 
red blood cell antibodies. Out of them, only 169 had 
identified sensibilisation only towards the RhD 
antigen, and 36 of them had a presence of multiply 
antibodies. 
Table 2: A risk to hemolysis according concentration of IgG 
subclasses 
 IgG1 IgG2 control IgG 
Dilution 1 : 1 1 : 100 1 : 1 1 : 100  1 : 10 
Reaction 2+ / / / / 3+ 
Interpretation Mild risk ( IgG1 low concentration) 
Reaction  3+ 2+ / / / 3+ 
Interpretation  High risk (IgG high concentration) 
Reaction  3+ 2+ 2+ / / 3+ 
Interpretation  High risk (IgG high concentration, IgG3 low concentration) 
Reaction  / / 3+ 2+ / 3+ 
Interpretation  High risk (IgG3 high concentration) 
Reaction  2+ / 3+ 2+ / 3+ 
Interpretation  High risk (IgG1 low concentration, IgG3 high concentration) 
Reaction  / / 2+ / / 3+ 
Interpretation  Mild risk (IgG3 low concentration) 
Reaction  3+ 2+ 3+ 2+ / 3+ 
Interpretation  High risk (IgG1 и IgG3 high concentration) 
 
The study researched the influence of 
subclasses to IgG anti-D on the intensity of HDFN at 
45 fetuses/newborns with symptoms of mild and 
severe HDFN. 
In order to determine the degree of risk to 
hemolytic, which depends on the number of IgG1 
and/or IgG3 molecules on the surface of red blood 
cells, as well as/or the presence of a complement, the 
test was performed by ID-cards DAT IgG1/IgG3. The 
gel contained two added dilutions of anti IgG1 and 
IgG3. The positive reaction with the first dilution 
matches coated red blood cells of 1000 IgG1 
molecules, i.e. 125 IgG3 molecules per red blood cell. 
The positive results with the second dilution points out 
to high concentration of IgG1 and/or IgG3 antibodies. 
 
 
Results 
 
IgG1 antibodies were detected in 15 samples 
of serums of sensibilised pregnant women towards 
the D antigen. Out of them, 7 had high concentration 
of IgG1, dilution 1:100. The tests performed on 
newborns came up with adequate results, i.e. 
symptoms of severe hemolytic disease. The rest of 
the 8 newborns demonstrated symptoms of mild 
HDFN or weak symptoms that needed no therapy. 
They have displayed low concentration of IgG1 that 
matches the dilution 1:1.  
IgG1 together with IgG3 was detected at 25 
pregnant women. At 10 of them the concentration to 
at least one of the subclasses was high, and at 6 of 
them there was a high concentration to both 
subclasses, received dilution 1:100. At all 16 
newborns the performed tests from the umbilical cord 
showed adequate high concentration as in their 
mothers, with symptoms of severe HDFN. At 9 women 
both subclasses showed low concentration, and the 
newborns developed mild HDFN.  
In 3 cases where only IgG3 anti-D antibody 
was detected, the newborns developed clinical picture 
of HDFN with a weak or mild intensity. There was not 
even one case of severe HDFN. 
Table 3: Correlation of the type and amount of IgG anti-D 
subclasses with the HDFN intensity 
IgG subclass HDFN Total HDFN weak/mild HDFN severe Dead fetus 
IgG1 16 8 7 1 
IgG1+ IgG3 26 9 16 1 
IgG3 3 3 /  
 
In two cases the pregnancy ended with a 
dead fetus. The first one in the 21 gestation week and 
it had IgG1 and IgG3 detected in merely high 
concentration, and the second case ended in the 25 
gestation week with also very high concentrations.  
 
 
 
Figure 2: Distribution of total HDFN (HBFN) according the IgG 
subclasses (left) and according the severity (right) 
 
At all 205 sensibilised pregnant women we 
have performed titer tests to antibodies during the 
whole pregnancy, within intervals of 2 to 4 weeks 
depending on the significance of the antibody 
received from the results.  
The correlation of the titer to anti-D antibodies 
in the mother’s serum and the intensity of HDFN were 
researched in 48 newborns. 
The titers between 1:8 and 1:32 resulted in 
most cases with weak and mild form of HDFN. Only in 
3 cases there was HDFN with symptoms of severe 
disease. In 4 cases there were no signs of HDFN. 
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At 12 women that had a titer between 1:32 
and 1:512, five of the newborns developed severe 
HDFN, and seven had symptoms of mild and weak 
intensity form. 
Table 4: Correlation of the titer of anti-D antibodies with the 
HDFN intensity 
Titer 
No symptoms or 
weak HDFN 
Mild HDFN Severe HDFN Total 
8-32 8 21 3 32 
32-512 2 5 5 12 
>512 1  2 3 
>1000   1 1 
 
In 3 cases the titer was higher than 512, and 
out of them one newborn had weak symptoms of 
HDFN, one developed severe HDFN and one ended 
with fetal death. Only in one case the titer reached a 
value higher than 1000, and it ended with a fetal 
death. 
 
Figure 3: Distribuition of the levels of anti-D antibodies according 
the severiti of HDFN (HBFN) 
 
At titers lower than 32, the test was repeated 
every 4 weeks till the 24 gestation week, and after that 
every 2 weeks, with recommendation of obstetrics 
monitoring. 
At titers higher than 32, the patients were 
immediately sent to intensive obstetrics monitoring. 
Depending on the results the titer was performed 
every 2 to 3 weeks, or immediately after performed 
invasive obstetrics procedure. 
 
 
Discussion  
 
If the mother’s alloimmunisation is diagnosed, 
and the biological father of the fetus is well known, 
phenotypisation of the father is necessary for 
detection of antigen presence towards which the 
mother’s antibodies are focused.  
If the father is antigen negative there is no 
possibility of the fetus to be antigen positive, and 
that’s why there is no risk of HDFN that could be 
caused by the mother’s alloantibodies. 
When the father is heterozygote antigen 
positive, it is possible nowadays, in cases of D, C, c, E 
and K antibodies, to determine the antigen status of 
the foetus by a DNA test through the mother’s plasma. 
In cases when the mother is sensibilised, and the 
result of the foetal genotypisation is negative, we 
avoid all further analysis and multiple monitoring 
procedures during pregnancy. 
If the result of the fetal genotypisation is 
positive, there is a necessity of immunohematology 
tests on every 2-4 weeks, by determining the type and 
amount of subclasses, and quantification of antibodies 
in general, as well as more detailed obstetrics tests 
related to risky pregnancy. 
There are several classes of antibodies. 
Regarding allosensibilisation during pregnancy only 
two classes are of interest, IgM and IgG. If the 
antibody is identified as IgM, it means that it cannot 
find the placenta, thus cannot cause HDFN. 
IgG is immunoglobulin that is most plentiful in 
the human serum. The subclasses differ in the 
constant region, especially in the structure of the 
upper CH2 domain. These regions are included in the 
bonding of the two receptors IgG-Fc (FcyR) I C1q. As 
a result, the subclasses have different effective 
functions in the sense of a trigger to FcyR – expessing 
cells, which produce phagocytosis or antibody – 
dependant cell cytotoxicity, and activation of the 
complement. There is an epytope on the Fc - receptor 
for neonatal Fc – receptor (FcRn), responsible for 
prolongation of the half life, placenta transport and 
IgG transport both ways through the mucosa surface 
[12]. 
IgG3 reacts more efficiently with the Fc – 
receptors on the macrophagys than the IgG1, but 
there is not enough data on in vivo destruction of red 
blood cells by IgG1 compared to IgG3 antibody [13]. 
IgG4 antibodies do not cause destruction of red blood 
cells since they have no capacity to activate a 
complement, neither can they interact with the 
macrophages. IgG2 is most often associated with the 
anti-A and anti-B antibodies. These antibodies can 
hardly cross the placenta and are less efficient 
mediators of macrophagys – induced clearance of red 
blood cells [13]. The serums containing anti-D 
antibodies most often reveal detection of IgG1 and 
IgG3, or just IgG1 or IgG3 subclass. The lytic activity 
of IgG3 is bigger than the one of IgG1 [12, 13]. 
According research data, IgG1 as a separate 
unit has a significantly wider specter of intensity 
compared to the IgG3, which is associated with a 
weak or mild HDFN, in concordance with scientific 
literature. IgG1 was detected in all three categories of 
HDFN, its distribution was significantly higher in cases 
of severe HDFN (р < 0.01). 
At 37.78% of the total number of tested 
patients, and at 65.38% of the samples which had two 
antibodies detected, IgG1 and IgG3 was the reason 
for severe HDFN. At 17.77% of the total number of 
tested patients, and at 50% of the samples which had 
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only IgG1detected, was the reason for serious 
intensity of HDFN. 
Not a single patient with IgG3 had symptoms 
of severe HDFN. When both subclasses are present 
IgG1 and IgG3, HDFN has a serious intensity 
compared to the presence of only IgG1 or IgG3 alone. 
IgG3 is more associated to mild and weak form of 
HDFN. 
The quantification of antibodies is usually 
performed by the titer method. The titer of the 
mother’s antibodies is the first step in evaluating RhD 
sensibilisation. A critical titer is defined as a titer 
associated to a significant risk of fetal hydrops [14]. 
The scientific literature gives different critical 
titers, from 8 to 32 for anti-D antibodies. The serum is 
recommended to be frozen and reestablished with the 
next sample by the same method. 
The trend of subsequent levels of antibodies 
together with the previous obstetrics anamnesis is 
considered to be more important than any isolated 
result in prediction of the disease’ intensity [15-17]. In 
the study paper the intensity of HDFN in most cases 
responded to the titer hight to the anti-D antibody. 
This is particularly true for titers higher than 512. In 
certain cases where the antibody titer was above the 
critical point, and the newborn didn’t show signs of 
HDFN with a serious intensity as expected, 
determination of subclasses complied to a low 
concentration of IgG1 and/or IgG3, or the mother’s 
serum contained other subclasses of IgG that have no 
capacity of complement activation, or are less efficient 
mediators of macrophagys -induced clearance of red 
blood cells. 
 In conclusion, the titers of the pregnant 
women serum that is lower than 32 and those higher 
than 1000 can well predict HDFN. In the first example 
there is a rare occurrence of severe HDFN, and they 
are quite often manifested with no or very insignificant 
symptomatology. In the second case, over 1000, the 
occurrence of severe HDFN is inevitable. The titers of 
anti-D antibodies between 64 and 512 have no exact 
predictive value. IgG1 and IgG3 subclasses of anti-D 
have no predictive value by themselves, and cannot 
foresee the outcome of HDFN. The research study 
results suggest that IgG1 and IgG3 should be 
included in a multi – parameter protocol for evaluation 
of the HDFN intensity. They can give a real 
assessment of the expected HDFN intensity in 
combination with the titer hight and the significance of 
the antibodies.  
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